BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22205110)

  • 1. Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.
    Valbuena C; Leitão D; Carneiro F; Oliveira JP
    Virchows Arch; 2012 Feb; 460(2):211-21. PubMed ID: 22205110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients.
    Hsu MJ; Chang FP; Lu YH; Hung SC; Wang YC; Yang AH; Lee HJ; Sung SH; Wang YF; Yu WC; Hsu TR; Huang PH; Chang SK; Dzhagalov I; Hsu CL; Niu DM
    Genet Med; 2019 Jan; 21(1):224-232. PubMed ID: 29875425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
    Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of Fabry disease patients.
    Rozenfeld PA; Croxatto O; Ebner R; Fossati CA
    Clin Exp Ophthalmol; 2006; 34(7):689-94. PubMed ID: 16970764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.
    Üçeyler N; Schröter N; Kafke W; Kramer D; Wanner C; Weidemann F; Sommer C
    PLoS One; 2016; 11(11):e0166484. PubMed ID: 27851774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry Disease Nephropathy: Histological Changes With Nonclassical Mutations and Genetic Variants of Unknown Significance.
    Santostefano M; Cappuccilli M; Gibertoni D; Fabbrizio B; Malvi D; Demetri M; Capelli I; Tringali E; Papa V; Biagini E; Cenacchi G; Galdi A; Donadio V; Liguori R; Zoli G; La Manna G; Pasquinelli G
    Am J Kidney Dis; 2023 Nov; 82(5):581-596.e0. PubMed ID: 37301502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedside Stereomicroscopy of Fabry Kidney Biopsies: An Easily Available Method for Diagnosis and Assessment of Sphingolipid Deposits.
    Svarstad E; Leh S; Skrunes R; Kampevold Larsen K; Eikrem Ø; Tøndel C
    Nephron; 2018; 138(1):13-21. PubMed ID: 28848191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
    Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
    Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal globotriaosylceramide deposits for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T/p.Arg118Cys: A family study.
    Cerón-Rodríguez M; Ramón-García G; Barajas-Colón E; Franco-Álvarez I; Salgado-Loza JL
    Mol Genet Genomic Med; 2019 Nov; 7(11):e981. PubMed ID: 31566927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease.
    Moura AP; Hammerschmidt T; Deon M; Giugliani R; Vargas CR
    Clin Chim Acta; 2018 Mar; 478():62-67. PubMed ID: 29274327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease.
    Apelland T; Gude E; Strøm EH; Gullestad L; Eiklid KL; Månsson JE; Reinholt FP; Houge G; Dahl CP; Almaas VM; Heiberg A
    Heart; 2014 Nov; 100(22):1793-8. PubMed ID: 25031264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis.
    van der Tol L; Svarstad E; Ortiz A; Tøndel C; Oliveira JP; Vogt L; Waldek S; Hughes DA; Lachmann RH; Terryn W; Hollak CE; Florquin S; van den Bergh Weerman MA; Wanner C; West ML; Biegstraaten M; Linthorst GE
    Mol Genet Metab; 2015 Feb; 114(2):242-7. PubMed ID: 25187469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy.
    Liguori R; Incensi A; de Pasqua S; Mignani R; Fileccia E; Santostefano M; Biagini E; Rapezzi C; Palmieri S; Romani I; Borsini W; Burlina A; Bombardi R; Caprini M; Avoni P; Donadio V
    PLoS One; 2017; 12(7):e0180581. PubMed ID: 28672034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry Nephropathy: An Evidence-Based Narrative Review.
    Del Pino M; Andrés A; Bernabéu AÁ; de Juan-Rivera J; Fernández E; de Dios García Díaz J; Hernández D; Luño J; Fernández IM; Paniagua J; Posada de la Paz M; Rodríguez-Pérez JC; Santamaría R; Torra R; Ambros JT; Vidau P; Torregrosa JV
    Kidney Blood Press Res; 2018; 43(2):406-421. PubMed ID: 29558749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of globotriaosylceramide (Gb
    Toupin A; Lavoie P; Arthus MF; Abaoui M; Boutin M; Fortier C; Ménard C; Bichet DG; Auray-Blais C
    Anal Chim Acta; 2018 Jul; 1015():35-49. PubMed ID: 29530250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
    Abaoui M; Boutin M; Lavoie P; Auray-Blais C
    Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.
    Lee MH; Choi EN; Jeon YJ; Jung SC
    Int J Mol Med; 2012 Dec; 30(6):1275-80. PubMed ID: 23007467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
    Manwaring V; Boutin M; Auray-Blais C
    Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
    Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.